CJC-1295 Ipamorelin research: two receptors, one pulse, and the trial nobody ran.

Before the details

The CJC-1295 Ipamorelin research splits cleanly into three buckets. First, what each peptide does on its own — and here the data is solid: CJC-1295 raised growth hormone for days in healthy people ^[1], and ipamorelin was the first growth-hormone-releasing peptide selective enough to leave the stress hormones alone ^[2]. Second, the synergy theory — old, human, and well grounded: a releasing-hormone signal plus a ghrelin-receptor signal produces a bigger pulse than either alone ^[3][4]. Third, the gap: nobody has run a controlled human trial of the two peptides mixed together. So the research below is best read as two strong single-peptide stories plus a mechanistic argument for why combining them should work — not as a study of the blend itself. Every number here is cited.

Cjc-1295 ipamorelin: the mechanism in full

The two peptides hit the same cell — the pituitary somatotroph — through two separate doors. CJC-1295 binds the GHRH receptor, a class-B G-protein-coupled receptor that signals through Gs to raise cAMP, driving growth-hormone synthesis and release. Ipamorelin binds GHS-R1a, the ghrelin receptor, which signals through Gq and phospholipase C to release intracellular calcium and trigger growth-hormone granule exocytosis. Because the two arms run through independent, complementary pathways, co-stimulation produces a pulse larger than either agent alone.

The ghrelin arm does a second thing: it opposes somatostatin, the brake on growth-hormone release. A 2021 review documents that ghrelin — and by extension synthetic GHS-R1a agonists like ipamorelin — co-localizes with GHRH in hypothalamic neurons, facilitates GHRH release by inhibiting somatostatin, and acts synergistically with GHRH to stimulate pituitary growth-hormone synthesis ^[10]. So the pairing both presses the accelerator and eases the brake.

Ipamorelin cjc 1295: the human CJC-1295 data

The pharmacokinetic backbone is Teichman 2006. In healthy adults aged 21 to 61, ascending single and multiple subcutaneous doses of CJC-1295 with DAC (30 or 60 µg/kg) raised mean plasma growth hormone two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days; after multiple doses, IGF-1 remained above baseline for up to 28 days ^[1]. That study established the multi-day pharmacodynamic profile that distinguishes the DAC form from everything shorter-acting.

The chemistry behind it is Jetté 2005. CJC-1295 carries an N-epsilon-maleimidopropionamide-lysine that covalently binds the Cys34 thiol of serum albumin; in rats this produced roughly a four-fold increase in growth-hormone area-under-the-curve over two hours versus unmodified hGRF(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours ^[5]. The DAC is the engineering that turns a minutes-long signal into a days-long one.

Growth hormone secretagogue: what "selective" bought ipamorelin

Ipamorelin's defining paper is Raun 1998. Across rat pituitary cells, anaesthetized rats, and conscious swine, ipamorelin released growth hormone as potently as GHRP-6 — but unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses more than 200 times the half-maximal dose for growth-hormone release; the swine half-maximal dose was 2.3 nmol/kg ^[2]. That clean separation between growth-hormone release and stress-hormone release is why ipamorelin is called the first selective growth-hormone secretagogue, and it is the main reason the modern stack uses it instead of the older, less selective peptides.

The ipamorelin scaffold is also unusually robust. It tolerates bulky modification: a meta-carborane hexapeptide built on the ipamorelin backbone retained high-efficacy GHS-R1a activation ^[13], and the backbone has been used as a template for radiolabelled ghrelin-receptor PET probes ^[14] — though the specific affinity values in that PET work belong to a different analogue, not to ipamorelin itself.

Cjc 1295 and ipamorelin: the synergy evidence — and its limits

The combination rationale rests on two studies, both about related peptides rather than this exact pair. Bowers 1990: in 18 normal adult men, submaximal GHRP doses (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated growth-hormone release synergistically, the two acting through independent mechanisms ^[3]. Cunha 2002: co-activating the cloned ghrelin and GHRH receptors in transfected HeLa cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, evidence of direct receptor cross-talk ^[4].

That is the whole foundation, and its limits matter. Both studies used short, pulsatile signals and related peptides — not CJC-1295 with DAC, and not ipamorelin specifically. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 Ipamorelin combination. Every efficacy claim about the blend is an inference from each component's separate literature plus this general synergy data. The research record supports "a GHRH signal plus a GHRP signal makes a bigger pulse." It does not contain "this specific blend was tested and did X."

Cjc 1295 dac: the read-across from tesamorelin

Because the blend itself is untested, the closest high-quality evidence for what sustained GHRH-pathway drive does in humans comes from an approved GHRH analogue. A 2026 meta-analysis of five randomized controlled trials of tesamorelin found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation ^[7]. This is read-across context for the GHRH arm — tesamorelin is a different molecule, but it confirms that stimulating the growth-hormone/IGF-1 axis can drive visceral-fat and liver-fat reduction with a manageable short-term safety profile.

The counter-signal belongs to ipamorelin. In growth-hormone-intact mice, twice-daily ipamorelin increased relative body fat and raised serum leptin and food intake — a growth-hormone-independent adipogenic effect working through appetite and leptin pathways ^[8]. That complicates any simple "fat-loss stack" framing: the ghrelin arm can push body fat up by a route that has nothing to do with growth hormone.

Where the evidence is thin, and the doping record

Most ipamorelin efficacy and dose-response data come from rodent models; human pharmacokinetics for ipamorelin are not formally published, and no controlled head-to-head human trial compares the combination with sermorelin, tesamorelin, or exogenous growth hormone. A 2020 andrology review discusses the role and limitations of growth-hormone secretagogues in men's-health practice, underlining the gap between marketed use and approved indications for this class ^[11].

The compounds also appear in the anti-doping literature. LC-HRMS analysis of preparations seized by Danish customs identified glycine-modified analogues of ipamorelin, GHRP-2, and GHRP-6 in seized doping material, demonstrating that anti-doping panels must cover N-terminal-modified secretagogue derivatives ^[12]. Both peptides are prohibited at all times in sport under WADA Section S2.